431 related articles for article (PubMed ID: 24950733)
41. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.
Mimeault M; Johansson SL; Senapati S; Momi N; Chakraborty S; Batra SK
Cancer Lett; 2010 Sep; 295(1):69-84. PubMed ID: 20303649
[TBL] [Abstract][Full Text] [Related]
42. Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer.
Liu QH; Yong HM; Zhuang QX; Zhang XP; Hou PF; Chen YS; Zhu MH; Bai J
Invest New Drugs; 2020 Apr; 38(2):350-359. PubMed ID: 31124054
[TBL] [Abstract][Full Text] [Related]
43. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.
Li L; Hao X; Qin J; Tang W; He F; Smith A; Zhang M; Simeone DM; Qiao XT; Chen ZN; Lawrence TS; Xu L
Gastroenterology; 2014 Apr; 146(4):1108-18. PubMed ID: 24397969
[TBL] [Abstract][Full Text] [Related]
44. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling.
Zhang Z; Wang F; Du C; Guo H; Ma L; Liu X; Kornmann M; Tian X; Yang Y
Cancer Lett; 2017 Aug; 402():213-224. PubMed ID: 28602977
[TBL] [Abstract][Full Text] [Related]
45. Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine.
Van den Broeck A; Gremeaux L; Topal B; Vankelecom H
BMC Cancer; 2012 Aug; 12():354. PubMed ID: 22894607
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
Pan Y; Li K; Tao X; Zhao Y; Chen Q; Li N; Liu J; Go VLW; Guo J; Gao G; Xiao GG
Pancreas; 2021 Oct; 50(9):1260-1266. PubMed ID: 34860809
[TBL] [Abstract][Full Text] [Related]
47. miRNA profiling in pancreatic cancer and restoration of chemosensitivity.
Singh S; Chitkara D; Kumar V; Behrman SW; Mahato RI
Cancer Lett; 2013 Jul; 334(2):211-20. PubMed ID: 23073476
[TBL] [Abstract][Full Text] [Related]
48. Characterization of side population cells isolated from the colon cancer cell line SW480.
Xiong B; Ma L; Hu X; Zhang C; Cheng Y
Int J Oncol; 2014 Sep; 45(3):1175-83. PubMed ID: 24926880
[TBL] [Abstract][Full Text] [Related]
49. ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway.
Ma H; Kong L; Liu L; Du Y; Zhu X; Wang J; Zhao W
Mol Carcinog; 2024 Jul; 63(7):1221-1234. PubMed ID: 38517039
[TBL] [Abstract][Full Text] [Related]
50. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil.
Kurata N; Fujita H; Ohuchida K; Mizumoto K; Mahawithitwong P; Sakai H; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
Int J Oncol; 2011 Aug; 39(2):473-82. PubMed ID: 21617862
[TBL] [Abstract][Full Text] [Related]
51. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
Asuthkar S; Stepanova V; Lebedeva T; Holterman AL; Estes N; Cines DB; Rao JS; Gondi CS
Mol Biol Cell; 2013 Sep; 24(17):2620-32. PubMed ID: 23864708
[TBL] [Abstract][Full Text] [Related]
52. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells.
Du Z; Qin R; Wei C; Wang M; Shi C; Tian R; Peng C
Dig Dis Sci; 2011 Mar; 56(3):741-50. PubMed ID: 20683663
[TBL] [Abstract][Full Text] [Related]
53. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
Solorzano CC; Baker CH; Tsan R; Traxler P; Cohen P; Buchdunger E; Killion JJ; Fidler IJ
Clin Cancer Res; 2001 Aug; 7(8):2563-72. PubMed ID: 11489840
[TBL] [Abstract][Full Text] [Related]
54. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
[TBL] [Abstract][Full Text] [Related]
55. Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer.
Onishi H; Morifuji Y; Kai M; Suyama K; Iwasaki H; Katano M
Cancer Sci; 2012 Jul; 103(7):1272-9. PubMed ID: 22486854
[TBL] [Abstract][Full Text] [Related]
56. ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.
Gharibi A; La Kim S; Molnar J; Brambilla D; Adamian Y; Hoover M; Hong J; Lin J; Wolfenden L; Kelber JA
Sci Rep; 2017 Aug; 7(1):10060. PubMed ID: 28855593
[TBL] [Abstract][Full Text] [Related]
57. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.
Kim MP; Fleming JB; Wang H; Abbruzzese JL; Choi W; Kopetz S; McConkey DJ; Evans DB; Gallick GE
PLoS One; 2011; 6(6):e20636. PubMed ID: 21695188
[TBL] [Abstract][Full Text] [Related]
58. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
[TBL] [Abstract][Full Text] [Related]
59. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
60. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1.
Zhou C; Qian W; Ma J; Cheng L; Jiang Z; Yan B; Li J; Duan W; Sun L; Cao J; Wang F; Wu E; Wu Z; Ma Q; Li X
Cell Prolif; 2019 Jan; 52(1):e12514. PubMed ID: 30341797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
